Glenmark Builds US OTC Lineup In Wockhardt Deal

Glenmark acquires a portfolio of generic OTCs from Wockhardt marketed in US including famotidine 10- and 20-mgs; cetirizine 5- and 10-mgs; lansoprazole 15-mg delayed-release; and olopatadine hydrochloride 0.1% ophthalmic solution.

• Source: Shutterstock

Indian pharma Glenmark Pharmaceuticals moves to further expand its OTC business in the US by striking a deal with Wockhardt to acquire a portfolio of generic equivalents of brand products.

Financial details of the transaction were not disclosed. Glenmark indicated only that it “continues to expand its OTC portfolio with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Alliance Pharma’s New Owners Will Instill ‘More Consumer-Oriented Mindset’

 
• By 

Private equity firms now in control of Alliance Pharma weighing úp plan to offload Rx business to help finance strategy to drive up sales and growth.

C&D Taps Hand Sanitizer Category With Touchland

 

Deal totaling as much as $880m extends C&D into additional product category with a brand it says is the fastest growing in the US hand sanitizer category and No. 2 brand in the category overall.

Venture Life Focuses On CHC As It Offloads CDMO

 
• By 

UK-based Venture Life is divesting its CDMO business and some non-core products to focus its attention on growing its consumer health operation.

Opella Goes Solo Promising To ‘Redefine The Future Of Self-Care’

 
• By 

Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.

More from Business

People On The Move: Appointments at Hermes, Assosalute, Moberg

 
• By 

A round up of the latest European consumer health exec moves: Hermes hires management board chair; Assosalute elects directors; Moberg appoints ex-Orkla Health CEO.

IQVIA Consumer Health: Digestive Category Driving Global OTC Market Growth

 
• By 

An increasing awareness of and interest in gut health helped the global OTC market grow by 4.6% in value terms in 2024, according to IQVIA Consumer Health.

Alliance Pharma’s New Owners Will Instill ‘More Consumer-Oriented Mindset’

 
• By 

Private equity firms now in control of Alliance Pharma weighing úp plan to offload Rx business to help finance strategy to drive up sales and growth.